<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392104</url>
  </required_header>
  <id_info>
    <org_study_id>2014-1296</org_study_id>
    <nct_id>NCT02392104</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service</brief_title>
  <official_title>Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William S. Middleton Memorial Veterans Hospital</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>William S. Middleton Memorial Veterans Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility, safety, and acceptability of
      implementing an extended interval of INR follow-up in Veterans on a stable dose of warfarin
      in the Anticoagulation Clinic at the William S. Middleton Memorial Veterans Hospital.

      All participants will be provided usual care from the anticoagulation clinic, except for the
      interval between INRs. If the participant continues to be on a stable dose of warfarin and
      the INRs are within the goal range of 2-3 (including lab variation), follow-up visits will be
      scheduled following an extended interval protocol. Patient satisfaction will be evaluated at
      various points throughout the study. Additionally provider satisfaction, confidence, and
      knowledge of the extended interval protocol will be analyzed. Bleeding and thromboembolic
      events will be evaluated to ensure the safety of an extended follow-up interval.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the feasibility, safety, and acceptability of
      implementing an extended interval of INR follow-up in Veterans on a stable dose of warfarin
      in the Anticoagulation Clinic at the William S. Middleton Memorial Veterans Hospital.

      All participants will be provided usual care from the anticoagulation clinic, except for the
      interval between INRs. If the participant continues to be on a stable dose of warfarin and
      the INRs are within the goal range of 2-3 (including lab variation), follow-up visits will be
      scheduled following an extended interval protocol, from 5-6 weeks, to 7-8 weeks, to 11-12
      weeks and then continued with 11-12 week visits if INRs continue to remain in goal range and
      appropriate for the patient. Patient satisfaction will be evaluated at baseline, 6-, 12-, and
      24-months. Additionally provider satisfaction, confidence, and knowledge of the extended
      interval protocol will be analyzed. Bleeding and thromboembolic events will be evaluated to
      ensure the safety of an extended follow-up interval.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2015</start_date>
  <completion_date type="Actual">June 25, 2017</completion_date>
  <primary_completion_date type="Actual">June 25, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of Participant Accrual</measure>
    <time_frame>up to 2.25 years</time_frame>
    <description>Number of participants who enroll vs. number of individuals invited</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Able to be Scheduled for at Least One 12-week Interval</measure>
    <time_frame>24 months</time_frame>
    <description>This outcome will determine the number of participants able to be scheduled for at least one 12-week interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Scheduled for at Least 4 Consecutive 12-week Intervals</measure>
    <time_frame>24 months</time_frame>
    <description>The outcome will determine the number of participants scheduled for at least 4 consecutive 12-week intervals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Frequency of Appointments From Baseline to End of Study</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>This outcome will evaluate the change in frequency of appointments from baseline to end of study (at 12 and 24 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding and Thromboembolic Events From Baseline</measure>
    <time_frame>24 months</time_frame>
    <description>This outcome will determine the number of bleeding and thromboembolic events from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Time in Therapeutic Range From Baseline</measure>
    <time_frame>6, 12, and 24 months</time_frame>
    <description>The outcome will evaluate the change in time in therapeutic range (TTR) from baseline (intention-to-treat)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction Through Total DASS Score</measure>
    <time_frame>baseline, 6 months, 12 months, 24 months</time_frame>
    <description>Patient satisfaction through total DASS score. DASS = Duke Anticoagulation Satisfaction Scale. 25-item scale.Higher numbers indicate worsening satisfaction ranging from 25-175. Seven-point ordinal scale (&quot;not at all&quot; = 1, &quot;very much&quot; = 7).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency and Type of Protocol Deviations From Both Participants and Study Staff</measure>
    <time_frame>Up to 2.25 years</time_frame>
    <description>This outcome determines the frequency and type of protocol deviations from both participants and study staff</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Anticoagulation</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in the study will be in the intervention arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  requirement for indefinite warfarin therapy

          -  target INR of 2-3

          -  stable weekly warfarin dose for the past 6 months (not more than a single, one-time
             adjustment (boost/omission) in the past 6 months, planned interruption for a procedure
             or surgery with INR(s) out of range in the past 6 months would not exclude a patient)

          -  a patient of the Madison VA anticoagulation clinic for the previous 12 months

        Exclusion Criteria:

          -  consistently drink â‰¥4 alcoholic beverages/day or a documented episode of alcohol
             binging in the past 6 months

          -  diagnosis of cancer and on active chemotherapy/radiotherapy in the past 3 months

          -  life expectancy of &lt; 1 year

          -  enrolled in other investigational drug protocols

          -  only receiving anticoagulation care at the Madison VA for part of the year (e.g.
             snowbirds)

          -  receiving visiting nurse services for INR monitoring

          -  thrombocytopenia (&lt;100K) within past 12 months

          -  history of bleeding or thromboembolism requiring medical intervention within past 6
             months

          -  treatment for active liver disease (e.g. hepatitis)

          -  diagnosis or documentation in EMR suggesting cognitive impairment

          -  activated power of attorney

          -  inability to provide informed consent

          -  non-English speaking

          -  unstable mental health disorder that impairs judgment

          -  history of non-adherence to anticoagulation clinic policies and procedures (i.e.
             missed appointments, self-adjustment of warfarin dose, nonadherence, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla Staresinic, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William S. Middleton Memorial Veterans Hospital</affiliation>
  </overall_official>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <results_first_submitted>October 16, 2019</results_first_submitted>
  <results_first_submitted_qc>November 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2019</results_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>William S. Middleton Memorial Veterans Hospital</investigator_affiliation>
    <investigator_full_name>Carla Staresinic</investigator_full_name>
    <investigator_title>Manager, Anticoagulation Services</investigator_title>
  </responsible_party>
  <keyword>International Normalized Ratio</keyword>
  <keyword>Warfarin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02392104/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Extended INR Follow-up Interval Group</title>
          <description>All patients in the study will be in the intervention arm.
Warfarin: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50">one participant enrolled but was removed prior to starting study protocol</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>discontinuation of warfarin</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>bleeding event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>transferred care to another doctor</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>INR goal range changed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>admitted to skilled nursing facility</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>INRs drawn by visiting nurse services</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention Arm</title>
          <description>All patients in the study will be in the intervention arm.
Warfarin: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.4" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAS-BLED score</title>
          <description>The HAS-BLED score evaluates a patient's bleeding risk. HAS-BLED is the official name of the tool to assess risk. Scores range from 0-9. Scores of 3 or higher indicate a high bleeding risk.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rates of Participant Accrual</title>
        <description>Number of participants who enroll vs. number of individuals invited</description>
        <time_frame>up to 2.25 years</time_frame>
        <population>107 invited to participate in the study, not all enrolled or started the study</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>All patients in the study will be in the intervention arm.
Warfarin: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Participant Accrual</title>
          <description>Number of participants who enroll vs. number of individuals invited</description>
          <population>107 invited to participate in the study, not all enrolled or started the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients invted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient enrolled in study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients analyzed for study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Able to be Scheduled for at Least One 12-week Interval</title>
        <description>This outcome will determine the number of participants able to be scheduled for at least one 12-week interval</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>All patients in the study will be in the intervention arm.
Warfarin: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Able to be Scheduled for at Least One 12-week Interval</title>
          <description>This outcome will determine the number of participants able to be scheduled for at least one 12-week interval</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Scheduled for at Least 4 Consecutive 12-week Intervals</title>
        <description>The outcome will determine the number of participants scheduled for at least 4 consecutive 12-week intervals</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>All patients in the study will be in the intervention arm.
Warfarin: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Scheduled for at Least 4 Consecutive 12-week Intervals</title>
          <description>The outcome will determine the number of participants scheduled for at least 4 consecutive 12-week intervals</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Frequency of Appointments From Baseline to End of Study</title>
        <description>This outcome will evaluate the change in frequency of appointments from baseline to end of study (at 12 and 24 months)</description>
        <time_frame>12 and 24 months</time_frame>
        <population>44 participants remained in the study at 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>All patients in the study will be in the intervention arm.
Warfarin: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frequency of Appointments From Baseline to End of Study</title>
          <description>This outcome will evaluate the change in frequency of appointments from baseline to end of study (at 12 and 24 months)</description>
          <population>44 participants remained in the study at 12 months</population>
          <units>visits per 12 months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Planned anticoagulation visits (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.67" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Planned anticoagulation visits (0-12 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.43" spread="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding and Thromboembolic Events From Baseline</title>
        <description>This outcome will determine the number of bleeding and thromboembolic events from baseline</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>All patients in the study will be in the intervention arm.
Warfarin: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding and Thromboembolic Events From Baseline</title>
          <description>This outcome will determine the number of bleeding and thromboembolic events from baseline</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of thromboembolic events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of major bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of serious bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Time in Therapeutic Range From Baseline</title>
        <description>The outcome will evaluate the change in time in therapeutic range (TTR) from baseline (intention-to-treat)</description>
        <time_frame>6, 12, and 24 months</time_frame>
        <population>49 participants at 12 months, 44 participants at 24 months</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>All patients in the study will be in the intervention arm.
Warfarin: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Time in Therapeutic Range From Baseline</title>
          <description>The outcome will evaluate the change in time in therapeutic range (TTR) from baseline (intention-to-treat)</description>
          <population>49 participants at 12 months, 44 participants at 24 months</population>
          <units>change in percentage of TTR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction Through Total DASS Score</title>
        <description>Patient satisfaction through total DASS score. DASS = Duke Anticoagulation Satisfaction Scale. 25-item scale.Higher numbers indicate worsening satisfaction ranging from 25-175. Seven-point ordinal scale (&quot;not at all&quot; = 1, &quot;very much&quot; = 7).</description>
        <time_frame>baseline, 6 months, 12 months, 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>All patients in the study will be in the intervention arm.
Warfarin: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction Through Total DASS Score</title>
          <description>Patient satisfaction through total DASS score. DASS = Duke Anticoagulation Satisfaction Scale. 25-item scale.Higher numbers indicate worsening satisfaction ranging from 25-175. Seven-point ordinal scale (&quot;not at all&quot; = 1, &quot;very much&quot; = 7).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.89" spread="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.99" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.83" spread="11.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.82" spread="15.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Frequency and Type of Protocol Deviations From Both Participants and Study Staff</title>
        <description>This outcome determines the frequency and type of protocol deviations from both participants and study staff</description>
        <time_frame>Up to 2.25 years</time_frame>
        <population>634 eligible participant visits</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>All patients in the study will be in the intervention arm.
Warfarin: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Type of Protocol Deviations From Both Participants and Study Staff</title>
          <description>This outcome determines the frequency and type of protocol deviations from both participants and study staff</description>
          <population>634 eligible participant visits</population>
          <units>percentage of visits</units>
          <param>Number</param>
          <units_analyzed>participant visits</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>participant visits</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="634"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>extended interval visits scheduled correctly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deviations too short</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deviations too long</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>Major bleeding was defined as a fatal or symptomatic bleed into a critical area or organ, bleeding leading to hospitalization, or transfusion of two units or more of packed red blood cells. This definition is the standard definition used by the Anticoagulation Clinic to report events.
Serious bleeding was defined as bleeding leading to emergency or urgent care visit or additional testing required.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention Arm</title>
          <description>All patients in the study will be in the intervention arm.
Warfarin: If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hemorrhoidal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Severe AKI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RLE cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Post-op monitoring for vascular procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Major bleeding</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Serious bleeding</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrea Porter, PharmD</name_or_title>
      <organization>William S. Middleton Memorial Veterans Hospital</organization>
      <phone>608-890-0742</phone>
      <email>andrea.porter@wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

